Over 1.7 million new cancers are diagnosed in the USA each year but nearly 3 out of 4 patients receive ineffective first-line treatment.

There is a critical unmet need to optimally match treatment options to patient specific tumors before treatment is administered. This is because cancer is a “personal” disorder where tumors from different patients are distinct in their makeup and response to treatment. Rapid and personalized care is needed for each patient on an individualized basis for maximum effectiveness and patient longevity.

At CerFlux we are creating advanced personalized medicine solutions to identify the most efficient and effective cancer treatments for each patient on an individualized basis. Our personalized medicine approach analyzes each patient’s specific tumor to rapidly identify and rank the best treatment options for a patient before treatment is administered. Compare this to the current approach where the patient has to suffer through ineffective, costly, and physically detrimental cancer protocols. The National Cancer Institute has highlighted this critical gap in “current methods to assess potential cancer treatments are cumbersome, expensive, and often inaccurate.” (NCI Provocative Questions 2011)

CerFlux POET^™

matches treatments to tumors before treatment is administered

CerFlux PEER^™

predicts efficacy of formulations early in the development cycle to save time and money